Abstract | The DNA repair enzyme O 6 -methylguanine-DNA methyltransferase (MGMT) antagonizes the genotoxic effects of alkylating agents. MGMT promoter methylation is the key mechanism of MGMT gene silencing and predicts a favorable outcome in patients with glioblastoma who are exposed to alkylating agent chemotherapy. This biomarker is on the verge of entering clinical decision-making and is currently used to stratify or even select glioblastoma patients for clinical trials. In other subtypes of glioma, such as anaplastic gliomas, the relevance of MGMT promoter methylation might extend beyond the prediction of chemosensitivity, and could reflect a distinct molecular profile. Here, we review the most commonly used assays for evaluation of MGMT status, outline the prerequisites for standardized tests, and evaluate reasons for difficulties in reproducibility. We critically discuss the prognostic and predictive value of MGMT silencing, reviewing trials in which patients with different types of glioma were treated with various chemotherapy schedules, either upfront or at recurrence. Standardization of MGMT testing requires comparison of different technologies across laboratories and prospectively validated cut-off values for prognostic or predictive effects. Moreover, future clinical trials will need to determine, for each subtype of glioma, the degree to which MGMT promoter methylation is predictive or prognostic, and whether testing should become routine clinical practice.
Introduction

O
6 -methylguanine-Dna methyltransferase (mGmt) is a ubiquitous Dna repair enzyme that has been highly conserved throughout evolution. mGmt is associated with resistance to alkylating agent cancer therapy, and modulation of this enzyme as a treatment target has been under investigation for over 2 decades.
1,2 mGmt rapidly reverses alkylation, including methylation, at the O 6 position of guanine by transferring the alkyl group to the active site of the enzyme. 3 although O
6
-alkylguanine is not the main lesion induced by alkylating agents, it seems to be the most cytotoxic one. lack of mGmt in the cell allows accumulation of O 6 -alkylguanine in the Dna, which, subsequent to incorrect pairing with thymidine, triggers mismatch repair, thereby inducing Dna damage signaling and, eventually, cell death. 4, 5 in accordance with this postulated mechanism, mismatch repair-deficient cells are highly resistant to alkylating agents, even in the absence of mGmt.
in this article, we critically review the prognostic and predictive value of MGMT silencing in gliomas, drawing on the results of trials in which various chemotherapy schedules were used to treat patients with these tumors. we discuss the assays that are most commonly used to evaluate MGMT status, outline the prerequisites for standardized tests, and consider possible reasons for di fficulties in reproducibility.
The MGMT gene and its promoter the MGMT gene is located on chromosomal band 10q26. its promoter lacks the constitutive regulatory elements known as the tata box and the Cat box, similar to many housekeeping genes, and contains a CpG island. CpG islands are genomic regions, typically of 300 -3,000 bp, that contain a high frequency of CG dinucleo tides (CpG sites), and are often located in the vicinity of the transcription initiation site. the region required for maximal promoter activity lies at the 5' end of the gene (from bp -953 to +202; transcription initiation site +1 bp) and comprises a minimal promoter, an enhancer region to which the MGMT enhancer-binding protein (meBP) binds, and a number of transcription factor binding sites, such as those for sp1 and aP1 ( Figure 1 ). expression levels of MGMT vary considerably between organs, with relatively low levels in the brain and the highest levels in the liver. tumors frequently exhibit higher levels of expression than do their tissue of origin. 
REVIEWS
the CpG island is located in the 5' region of MGMT (bp -552 to +289) and includes 97 CpGs (Figure 1 ), which are usually unmethylated in normal tissues. methyl-CpGbinding proteins, such as methyl-CpG-binding protein 2 (meCP2) and methyl-CpG-binding domain protein 2 (mBD2), bind to aberrantly methylated sequences, leading to alterations of chromatin structure and preventing binding of transcription factors, thereby silencing the gene (Figures 1 and 2a) . 6 some studies have provided insight into the relationship between gene expression and the patterns and localization of dense CpG methylation in the MGMT promoter. 6, 7 two regions that are prone to high levels of methylation have been identified, of which the region comprising the enhancer element seems to be more critical for the loss of MGMT gene expression upon methylation, on the basis of luciferase reporter assays interrogating dif ferent regions of the methylated promoter. 6, 7 Hence, most methylation-specific tests are designed to interrogate this region (Figure 2b ).
MGMT promoter methylation in gliomas
the first striking observations on a potential predictive value of mGmt protein levels, as determined by immuno fluorescence microscopy, in patients with malignant glioma were made more than 10 years ago. 8, 9 Patients with low levels of mGmt seemed to derive considerably more benefit from carmustine (BCnu) than those with high levels. similarly, low levels of mGmt protein, as detected by immunohistochemistry, predicted prolonged progression-free survival (PFs) in patients with glioma MGMT status has become a parameter for stratification of patients with glioma within clinical trials treated upfront with temozolomide, 10 or prolonged overall survival in patients with newly diagnosed, inoperable glioblastoma treated with neoadjuvant temozolomide. 11 Decreased levels of mGmt protein can be attributed to epigenetic silencing mediated by MGMT gene promoter methylation, which can be assessed by a simple methylation-specific PCr (msP). a correlation with survival was demonstrated when patients with glioma were treated with nitrosoureas 12 or temozolomide, 13 strongly suggesting that MGMT promoter methylation assessment could provide a prognostic or predictive biomarker for benefit from alkylator-based chemotherapy added to radiotherapy. subsequently, in the randomized european organization for research and treatment of Cancer (eortC) 26981-22981-national Cancer institute of Canada (nCiC) Ce.3 trial, 14, 15 MGMT pr omoter me thylation was shown to predict prolonged PFs specifically in patients treated with temozolomide and radiotherapy, consistent with the idea that methylation predicts benefit from alkylating agent chemotherapy rather than simply being yet another prognostic marker. By contrast, only a slight trend was observed towards longer PFs in patients with methylated versus unmethy lated tumors who were treated with radiotherapy alone. 15 this study used a nonquantitative gel-based msP assay and dichotom ized patients into methylated and un methylated groups (45% versus 55%). Quantitative assays, such as real-time, quantitative PCr (qmsP), suggest that a subgroup of patients with intermediate methylation exists, representing a 'gray zone' in the test results. this observation could account for the fact that some patients with MGMT-methylated tumors seemed to derive no benefit from temozolomide, whereas some patients in the unmethylated group did benefit from the treatment. the modest effect of temozolomide in patients lacking MGMT promoter methylation has provoked an ongoing discussion as to whether MGMT testing should be made mandatory, and whether temo zolomide should be withheld from patients with tumors that lack MGMT promoter methylation.
the possible predictive value of MGMT promoter methy lation specifically for the benefit derived from alkylating chemotherapy in glioblastoma patients has revieWS recently been challenged in patients with anaplastic glioma. a trial by the German Cancer society's neurooncology working Group (noa-04) showed prolonged PFs and overall survival in wHo grade iii anaplastic glioma patients with MGMT promoter methylation, irrespec tive of initial treatment with radiotherapy or alkylating agent chemotherapy, temozolomide or procarbacin, CCnu and vincristin (PCv). 16 similarly, in the eortC trial 26951 on adjuvant PCv chemotherapy, PFs was prolonged in patients whose tumors showed MGMT pr omoter methylation, independent of the administration of alkylating agent chemotherapy.
17 since no evidence exists that mGmt is involved in the repair of radiationinduced Dna damage, other, as yet unknown, genetic alterations associated with MGMT promoter methylation and predictive for sensi tivity to irradiation could be operating in MGMT-methylated anaplastic gliomas. these findings raise the question of whether MGMT promoter methy lation is merely an epiphenomenon of other important predictive and prognostic markers, and they also underline the idea that grade iii and grade iv gliomas need to be studied as separate entities. Assessing MGMT status in tumor tissue the potential clinical utility of MGMT status as a biomarker in gliomas has led to an ongoing debate re garding how this status should be assessed-by promoter methylation analysis, at the level of mrna or protein expression, or by enzyme activity-and which specific procedure is best suited for routine clinical applications. 18 ,19 a biomarker test for MGMT status needs to be standardized, suitable for high-throughput analyses and reproducible in independent laboratories, and must have a clinically relevant cut-off point. the test should allow prospective patient selection and individualized therapy, thereby pursuing the strategy of personalized medicine for patients with brain tumors.
enzyme activity the enzymatic activity of mGmt can be assessed in cell lysates from freshly resected or frozen tumor tissue. the main drawbacks to this approach are the po tential contamination by non-neoplastic cells, 20 and the requirement for rapid and standardized processing of the samples. By means of an assay that measured the transfer of 3 H-labeled methyl groups from the O 6 position of guanine to protein in the cell extract, mGmt activity was shown to be increased in recurrent tumors specifically in patients who had received alkylating agent chemotherapy. 21, 22 However, such data have not been generated in a controlled, prospective manner and with parallel assessment of MGMT promoter methylation.
immunohistochemistry the early studies that used immunofluorescence detection in malignant gliomas, 8, 9 as well as more-recent studies in progressive low-grade oligodendroglial tumors 23 or newly diagnosed glioblastoma, 11 reported that low mGmt protein levels had predictive value for the response to alkylating agents. the clinical value of immunohistochemical detection of mGmt protein in human gliomas, however, remains controversial for several reasons. First, mGmt assessment by immunochemical techniques has failed to correlate consistently with outcome. 18, 24 second, a high interobserver variability, even among expert neuro pathologists, casts doubt on the reproducibility of this method of assessment. revieWS third, many authors have failed to identify a correlation between MGMT promoter methylation assessed by msP and protein levels in glioma tissue assessed by immunochemistry. 18,24 -26 one ex planation for this lack of correlation is the considerable and highly variable contamination of glioma tissue sections with non-neoplastic cells expressing mGmt, which are not always easy to distinguish from tumor cells (Figure 3) . Furthermore, published cut-off levels employed to define low versus high mGmt expression are highly variable (ranging from >10% to >50% positive cells). 18 the extent to which such variation accounts for the conflicting results remains unknown.
mrnA expression MGMT mrna levels can be determined in fresh surgical specimens, although contamination by mrna from non-neoplastic cells makes the results difficult to interpret. In situ hybridization might circumvent this problem, but specific delineation of tumor cells, as well as careful and uniform handling of the samples to prevent degradation, remains a challenge, as does any effort at quantification.
MGMT promoter methylation the widespread recognition of the value of the MGMT promoter methylation status derives from its identification as a predictive marker for prolonged PFs and overall survival in temozolomide-treated patients in the eortC-nCiC study. this study used a gel-based msP assay that is now widely employed. 15, 27, 28 Diagnostic methylation-specific assays aim at predicting the activity of the whole MGMT promoter by interrogating only a fraction of the CpGs for their methy lation status. in other words, the test needs to predict overall dense promoter methylation that is associated with silencing of the gene (Figure 2a ). the CpGs interrogated by different methylation-specific assays are depicted in Figure 2b . the principle for the discrimination of un methylated from methylated sequences that is used by most methylation-specific assays is based on a bisulfite treatment step that converts unmethylated cytosine-but not 5-methylcytosine-in the Dna to uracil (Figure 4 ). subsequent detection and quantification of the methylated and unmethylated sequences can be performed by various technologies to create semiquantitative or qu antitative assays (table 1) . msP is the most commonly used technology at present (tables 2 and 3). this technique uses methylationspecific primers, each of which is designed to bind only to completely methylated or unmethylated sequences. each primer typically interrogates a series of three to five CpGs. [27] [28] [29] msP can be performed using real-time PCr platforms that allow standardization, high-throughput analysis, and definition of cut-off points. 30, 31 other quantitative or semiquanitative methods include methylation-specific pyrosequencing, which interrogates between 4 and 12 CpGs, 32 and methylation-specific clone sequencing. restriction enzymes that differen tiate between methylated and unmethylated sequences are used in combined bisulfite restriction analysis (CoBra) 32 and methylation-specific multiplex ligation-dependent probe amplification (ms-mPla). 33 the latter te chnique does not depend on bisulfite conversion. recently de veloped technologies that analyze bisulfite-converted Dna include methylation-sensitive high-resolution melting (ms-Hrm; a PCr-based method that differentiates the melting behavior of the amplicons derived from methylated and unmethy lated sequences), 34 bead arraybased technologies, 35 mass spectroscopy, 36 and de naturing high-performance liquid chromatography. 37 each technology must define a cut-off point for the prognostic effect of the MGMT methylation status, which needs to be validated prospectively. Quantitative assays are more amenable to definition of technical cut-off points and quality control than are qualitative assays, as illustrated by qmsP. 29, 31 Completely quantitative or semiquantitative assays that normalize to a control gene or the copy number of the unmethylated MGMT promoter sequence might underestimate MGMT methylation, because contaminating nontumoral tissue will contribute to the signal of the normalizing gene. the tissue used for Dna isolation must, therefore, be macro dissected by the neuropathologist, so as to avoid infiltration zones, lympho cyte infiltrates, and regions dominated by vascular proliferation. samples consisting of compact tumor tissue of sufficient size; for example, four paraffin sections with a compact tumor surface of 0.5 × 1 cm, generally provide good results. stereotactic biopsies should be controlled for tumor content, and usually only yield sufficient Dna when obtained frozen. 25 tissues should be fixed in bu ffered formalin. overfixation decreases the quality of the Dna owing to formation of crosslinks, and can impede successful testing.
Bisulfite conversion is the most critical step, since incomplete conversion yields an apparently 'methylated' CpG. the procedure should, therefore, be controlled for completion of the reaction. 29 a number of commercial kits work reliably. Bisulfite-treated Dna is unstable and should be used rapidly, although storage at -20 °C in aliquots will slow down the decay.
to date, msP is the only test that has repeatedly been shown to be of predictive or prognostic value in clinical trials (tables 2 and 3).
13,38 at present, qmsP 31 is being used
Various technologies
Quanti cation of 'methylated' sequences Figure 4 | Bisulfite conversion of tumor DNA. Treatment of DNA with bisulfite results in the conversion of unmethylated cytosine into uracil, which is replaced by thymidine in the subsequent PCR step. By contrast, 5-methylcytosine ( m C) will not be converted and thus remains as a cytosine. Incomplete bisulfite conversion of unmethylated cytosine will be interpreted as methylation in the subsequent quantification step using any technology and will, therefore, yield a false-positive result.
revieWS for patient selection in the CentriC trial (Clinicaltrials. gov 39 nCt00689221). this trial is assessing a role for cilengitide in newly diagnosed glioblastoma in light of promising phase ii data indicating that the activity of this drug is restricted to patients with MGMT promoter methyla tion (stupp, r. et al., unpublished work). Furthermore, on the basis of a strong preclinical rationale, the activity of enzastau rin and radiotherapy in newly diagnosed glioblastoma is being assessed only in patients with an unmethylated MGMT promoter. 40 the results of prospective validation of a qmsP-based test, 31 in a randomized phase iii trial of glioblastoma patients treated with temozolomide in the radiotherapy oncology Group (rtoG) 0525 eortC intergroup trial (Clinicaltrials. gov 39 nCt00304031), are expected by early 2010. the quantitative evaluation of MGMT methylation in this trial is expected to provide a clinically relevant cut-off point, as opposed to the technical cut-off already defined. 31 validation of other technologies is awaited. Given the large variation of 30-60% MGMT methylation reported in the literature for glioblastoma, clinical validation of cut-offs for individual tests is crucial. methylation testing revieWS performed outside the academic trial context should also follow a specified protocol that lends itself to independent reproduction. in the future, the use of prospectively validat ed tests should become standard.
The role of MGMT in glioma subtypes glioblastoma the MGMT promoter methylation status, as determined by msP, is the strongest prognostic factor for outcome in patients with newly diagnosed glioblastoma, and is a power ful predictor of response to alkylating chemo therapy (table 2) . 12,13,15,38,41,42 the 2 year and 5 year survival rates in patients with a methylated MGMT promoter treated with concomitant and adjuvant temozolomide were 49% and 14%, respectively, while the corresponding figures for patients initially treated with radiotherapy only were 24% and 5%. of patients with an unmethylated MGMT promoter, 15% and 8% were alive at 2 years and 5 years, respectively, after treatment with combined chemo radiotherapy, compared with 2% and 0% in those initially treated with radiotherapy alone. 43 the small improvement in outcome even in the patients with an unmethy lated MGMT promoter could be attributable to the a forementioned gray zone separating methylated and unmethylated tumors, and the consequent somewhat arbitrary separation into two groups. incorrect test results, misdiagnosis of some lower grade gliomas, differences in post-progression therapy, and individual variability due to other, as yet unrecognized, prognostic factors could also explain the marginally improved outcome of combinedmodality treatment in patients with an unmethylated MGMT promoter. the prognostic relevance of MGMT promoter status has been confirmed in elderly glioblastoma patients treated with concomitant and adjuvant temozolomide. 44 in addition, the observation that 74% of patients with glioblastoma who survive for >5 years have MGMT promoter methylation-as opposed to <50% in an unselected population of glioblastoma patients-also underlines the prognostic value of MGMT status. 45 nevertheless, longterm survival can be observed even in the absence of MGMT promoter methylation, indicating that MGMT promoter methylation is only one aspect of a very complex bi ological system. 45, 46 the extent of MGMT methylation, as measured by pyrosequencing, has been proposed to be a prognostic factor in glioblastoma patients treated with temo zolomide and radiotherapy. 47 Patients with >29% MGMT methylation over the 12 CpG sites measured had a significantly better outcome than patients with >9% but ≤29% methylation, a clinically interesting finding that will need prospec tive validation. the authors defined 9% methylation as the cut-off point for determining outcomes between methylated and unmethylated tumors. this cut-off for methylation was considered to be statistically different from the background determined in non-neoplastic brain. leaving aside the possibility that methylation detected at a low level could reflect a falsepositive result, a low methylation average could, in some cases, signify the presence of only a few methylated CpGs, as suggested by the unsuper vised analysis of the MGMT methy lation pattern used in this study. such low positive scores might not necessarily reflect the dense methylation that is required for silencing of the gene. in comparison, msP would only recognize dense methylation and would not detect small numbers of methylated CpGs, highlighting the different information content of the results render ed by these two technologies. revieWS in contrast to newly diagnosed glioblastoma, the predictive value of MGMT promoter methylation has remained controversial in recurrent glioblastoma. the absence of a strong predictive effect on tumor response or outcome with various temozolomide adminis tration schedules [48] [49] [50] suggests that mGmt-independent mechanisms of resistance have a predominant role in the setting of recurrent glioblastoma. nevertheless, patients with MGMT-methylated tumors still showed improved survival in these series, although no such effect was seen in a recent study from Belgium. 51 selection for loss of mismatch repair proteins, such as msH6, could be involved in a minority of patients. [52] [53] [54] In vivo evidence for the direct involvement of mGmt in the response of glioblastoma to alkylating agents has been provided by the Cancer Genome atlas report. 55 mutation analyses of 601 genes in 91 matched tumor and normal samples identified a hypermutator phenotype in the recurrent glioblastoma of a subset of 7 of 19 patients pretreated with alky lating agents. this phenotype was much more common in tumors with a methylated MGMT promoter (6 of 6 MGMT-methylated cases) than those with an unmethylated promoter. moreover, in all 6 treated and MGMTmethylated glioblastomas that were hyper mutated, at least one of the mismatch repair genes MLH1, MSH2, MSH6 and PMS2 was mutated, compared with only 1 of 84 non-hypermutated, untreated glioblastomas. the gene mutation pattern, including mutations of mismatch repair genes, was different in the 6 patients whose glioblastoma carried a methylated MGMT promoter from the pattern seen in unmethylated and treated tumors (n = 13). this discovery was compatible with a deficiency in repair of alkylated guanine residues, as reflected in a strong predominance of G:C to a:t transitions at non-CpG sites (146/181 [81%] mutations in the 6 treated, MGMTmethylated patients versus 29/99 [29%] in the 13 treated, MGMT-unmethylated patients). these findings are consistent with escape from MGMT methylation-mediated sensitivity to the alkylating drug by selection for mismatch repair deficiency.
the value of temozolomide in the setting of recurrent glioblastoma, including its relationship with MGMT promoter methylation status, must now be determined in patients who have already been exposed to temo zolomide in the first-line setting, 56, 57 as is being pursued in the DireCtor trial (Clinicaltrials.gov 39 nCt00941460).
Anaplastic glioma the noa-04 trial showed no difference in PFs or overall survival between patients with anaplastic glioma started on radiotherapy alone and patients started on temozolomide or PCv alone. interestingly, MGMT promoter methylation predicted prolonged PFs irrespective of the initial treatment. 16 similar results were obtained in the eortC trial 26951, in that MGMT promoter methy lation was prognostic for PFs in both arms-radiotherapy alone and radiotherapy followed by PCv.
17 the high corre lation of MGMT promoter methylation with the 1p19q codeletion 17, 58, 59 and isocitrate dehydrogenase (IDH) gene mutations, 60 which are known to be favorable prognostic factors in anaplastic glioma, 16, 61, 62 might indicate that epigenetic deregulation of MGMT occurs in a specific pathogenetic context in anaplastic gliomas. since MGMT promoter methylation is prognostic and not predictive for chemotherapy response in anaplastic gliomas, a methylated MGMT promoter should not be used to justify the upfront treatment of these tumors with temozolomidebased radiochemotherapy in the absence of appropriate data from studies such as Catnon (Clinicaltrials.gov 39 nCt00626990).
low-grade glioma an initial study on 49 patients reported that MGMT promoter methylation is a negative prognostic factor for PFs in patients with low-grade astrocytomas. 63 the population was, however, mixed, in that approximately one-quarter of the patients were untreated after surgery, one-quarter received radiotherapy, and half received interferon only. By contrast, protracted treatment with temo zolomide in a phase ii study in low-grade glioma showed improved outcome in patients with MGMT promoter methylation. 64 one might speculate that the dif ferences in outcome attributed to the MGMT status were, in fact, due to the alkylating agent therapy that was present in the latter study. Both MGMT promoter methylation 65 and low mGmt protein levels 23 were reported to predict a favorable response to temozolomide in low-grade oligodendrogliomas. in addition, a correlation exists between MGMT promoter methylation and the 1p19q co-deletion and mutations of the IDH1 gene in these tumors, 58, 60 as well as in anaplastic gliomas (see above).
16,60 which of these changes, or other aberrations yet to be identified, contribute most to the chemosensitivity of these tumors remains to be elucidated.
Pseudoprogression, relapse and MGMT status the idea that MGMT methylation status might have clinical relevance was supported by the analysis of peculiar false-positive neuroradiological patterns mimicking early disease progression in patients after radiochemotherapy involving temozolomide. these patterns, termed 'pseudoprogression' , are usually seen in the first 3 months after completion of radiotherapy with concomitant chemotherapy, and may be more common in patients with MGMT-methylated tumors, possibly signifying the extent of cytotoxic effects of treatment. 66 some have speculated that the increase in overall survival observed in patients with glioma treated with temozolomide concomitant with radiotherapy could be associated with altered patterns of relapses. For many years, relapse inside the radiotherapy field in 90% of all cases has been the rule for patients with glioblastoma. a recent analysis of the eortC 26981-22981-nCiC Ce.3 trial showed a frequency for distant recurrences of 20%. 67 this analysis, which was carried out using a novel observer-independent tool, demonstrated no differences in the recurrence pattern (distant versus local) according to either therapy or MGMT status. in another series, MGMT promoter methylation was associated with an increased frequency of distant recurrences, defined as revieWS recurrences with ≤20% enhancing tumor residing inside the 95% isodose of the radiation field. 68 the best methodo logy to determine this clinically relevant point needs to be confirmed prospectively.
A role for routine MGMT testing?
MGMT promoter methylation is now recognized to be a relatively early molecular lesion in the pathogenesis of gliomas. the frequencies of methylation seem to be specific to the glioma subtype and malignancy grade, as depicted in Figure 5 . whether a methylated MGMT promoter has the same relevance in all types of gliomas and for all grades of malignancy, however, remains a matter for debate. in glioblastoma, for example, in contrast to all other glioma subtypes, one MGMT allele is frequently lost by deletion of one copy of chromosome 10. loss of one allele plus methylation is likely to have more-profound effects on mGmt expression than methylation alone, which may only affect one allele.
the true value of MGMT promoter methylation as a diagnostic and prognostic marker suitable for treatment decisions depends in part on the answers to several crucial questions. First, which area of the gene is most relevant for silencing through methylation? second, how do we set the clinically relevant cut-off point in quantitative assays? third, how homogeneous is the MGMT promoter methylation pattern within a given tumor? last, how stable is the methylation pattern throughout the course of disease and on disease progression? importantly, at present we have no appropriate alternative treatments for patients whose MGMT promoter methylation profile does not suggest a substantial benefit from alkylating agent chemotherapy. withholding such treatment on the basis of this profile, therefore, would seem to be inappropriate at this stage. a thorough analysis of two to four biopsy specimens from each of 25 wHo grade iii or iv gliomas revealed that MGMT promoter methylation is a highly homogeneous marker in malignant gliomas. msP and sodium bisulfate sequencing showed identical results, and only one tumor showed inconsistent results between biopsies. 25 little is known regarding therapy-induced changes in MGMT promoter methylation or mGmt expression levels in the tumor. neither dexamethasone nor irradiation induced MGMT gene transcription in glioma cells in vitro. 69 in tissue culture and animal studies, however, temozolomide strongly induced mGmt protein expression in temozolomide-resistant glioma cells lacking MGMT promoter methylation. 70 loss of MGMT promoter methylation might represent a key mechanism by which patients with initially methylated tumors eventually acquire resistance to temo zolomide, leading to progression or relapse. Data on changes in methylation status, however, remain scarce. a study of 14 patients with initial low-grade astrocytoma his tology showed that three patients acquired methylation at recurrence, but no initially methylated tumor lost its methylation. 63 another small study reported changes in methylation status in three of ten patients, but a possible relationship with treatment was not explored. 71 of ten patients treated with temozolomide chemo radiation in phase ii or iii trials, 13, 15 eight tumors remained unchanged (one unmethylated and seven methylated), while one gained and another lost MGMT promoter methylation (Hegi, m. e., unpublished work). similarly, an analysis of paired primary and recurrent glio blastoma tissue samples from patients initially treated with radiotherapy and temozolomide by the German Glioma network indicated that the MGMT promoter methylation status remained stable in the vast majority of patients (reifenberger, G. and weller, m., unpublished work). Hence, treatment resistance seems not to be associated with changes in the MGMT methylation status.
taken together, the data summarized so far indicate that the determination of MGMT promoter methylation undoubtedly yields prognostic information, but is rarely useful for clinical decision-making in individual patients. Could MGMT testing have a role in clinical trials for patients with glioma? several current trial concepts use the MGMT status, as determined by msP, for stratification or as an inclusion criterion, limiting enrollment to patients either with methylated or unmethylated tumors. moreover, in europe at least, withholding temozolomide from patients with newly diagnosed glioblastoma without MGMT promoter methylation is considered to be justified in the context of clinical trials to test the effect of a new compound. indeed, such an approach is being used in a current phase ii study led by the eortC, comparing radiotherapy plus temsirolimus versus radiotherapy plus temozolomide. this view is not, however, shared by most neuro-oncologists in the us. Tables 2 and 3 and several additional references. 25,58,63,84 -93 Most studies used gel-based methylation-specific PCR. Glioblastoma shown as 'GBM' are not listed under PrGBM or ScGBM, with the exception of one population-based study. Abbreviations: AA, anaplastic astrocytoma; AO, anaplastic oligodendroglioma; AOA, anaplastic oligoastrocytoma; GBM, glioblastoma; LA, low-grade astrocytoma; O, oligodendroglioma; OA, oligoastrocytoma; PrGBM, primary glioblastoma; ScGBM, secondary glioblastoma. revieWS MGMT-depleting strategies the presence of mGmt as a key Dna repair protein is an undisputed mechanism of resistance to chemotherapy with alkylating agents. strategies to overcome mGmtmediated resistance have been and are being pursued. mGmt-depleting agents, such as O 6 -benzylguanine (O 6 -BG), act as a pseudosubstrate for mGmt, which in turn is consumed and subsequently targeted for proteasomal degradation. thus, de novo synthesis of mGmt is required to maintain Dna repair. systemic application of O 6 -BG was shown to decrease mGmt activity in glioma tissue when assessed 6 hours later, but was no longer effective at 18 hours, 72 suggesting that mGmt is rapidly resynthesized in vivo. accordingly, multiple daily dosing would be necessary to maintain low mGmt activity. Furthermore, O 6 -BG depletes mGmt nonselectively, resulting in substantial systemic toxicity, most notably dose-limiting myelosuppression, which necessitates substantial dose reductions for nitrosoureas or temozolomide. the clinical experience has, therefore, been disappointing overall in recurrent glioblastoma, although some responses (16% [5/32] ) were reported in patients with anaplastic glioma. 73 the feasibility of administering O 6 -BG locally into the tumor cavity via an ommaya reser voir, in combination with systemic temozolomide, has been explored in a single patient. 74 with the aim of increasing the dose-limiting tolerance of the bone marrow towards alkylating chemotherapy or inducing long-term selection of genetically modified hematopoietic stem and precursor cells (HsCs), HsCs were transduced with a retroviral vector that expresses the Pro140lys mutant of mGmt (mGmt*), which confers resistance to inhibition by O
-BG. rhesus macaque experiments with CD34
+ HsCs demonstrated the feasibility of generating long-term repopulating mGmt* HsCs. O 6 -BG plus temozolomide or BCnu treatment provided chemoprotection of progenitor cells but no selection of long-term repopulating HsCs. 75 a phase i clinical trial of this approach for patients with newly diagnosed glioblastoma or grade iii astrocytoma was opened in 2006 (Clinicaltrials.gov 39 nCt00272870), but was suspended owing to low recruitment levels and drug availability.
since temozolomide is itself a substrate for mGmt, alternative, more-protracted dosing regimes of temozolomide have been explored in first-line and recurrent glioblastoma settings. the rtoG-0525-eortC intergroup trial has set out to determine whether alternative dosing of temozolomide in the adjuvant phase after completion of the concomitant treatment phase, using a 3 weeks on-1 week off schedule, could overcome resistance to chemotherapy in the nonmethylated population in the first-line setting. even if this trial proves to be positive for patients without MGMT methylation, the question of whether the success depended on a dose-intense temozolomide-dependent depletion of mGmt levels in the tumor cells still remains open. two small phase ii trials aiming to improve PFs and overall survival by intensifying alkylating agent treatments have resulted in clinical benefits only for patients with MGMT promoter methylation. 38, 76, 77 the use of dose-intense temozolomide in patients with recurrent disease resulted in PFs rates at 6 months of 30-45%, 48, 49, 56 suggesting superiority over conventional dosing using the 5 out of 28 days sc hedule (21%). 78 notably, none of these studies have been able to demonstrate that the presumed superiority of doseintense temozolomide regimens is truly mediated by mGmt depletion, because serial biopsies of brain tumors are ethically not feasible. moreover, preliminary results of the uK medical research Council Br12 trial, which allocated patients with recurrent anaplastic astrocytoma or glioblastoma randomly, in a noncomparative design, to temozolomide for 5 out of 28 days or 21 out of 28 days, indicated an inferior outcome with the co ntinuous adminstration schedule.
Conclusions
MGMT promoter methylation has emerged as an important molecular marker in patients with gliomas. Furthermore, the eortC-nCiC trial has suggested that MGMT promoter methylation is not only a prognostic marker, but is also a predictive marker for response to temozolomide in patients with newly diagnosed glioblastoma. 15 emerging data indicate that MGMT promoter methylation has strong prognostic relevance following therapy with both radiation therapy and alkylating chemo therapy in patients with anaplastic glioma. 16, 17 in this setting, MGMT promoter methylation is likely to be indicative of a broader molecular phenotype with prog nostic significance. Correlative analysis with other prognostic molecular markers, such as the 1p19q codeletion or IDH1 and IDH2 mutations, should further clarify the importance of MGMT promoter methylation in this patient population. in anticipation of the results of ongoing prospective phase iii trials incorporating MGMT promoter methylation status, and validation of a diag nostic assay, treatment decisions should not yet be based on MGMT promoter methylation status outside clinical trials. However, all investigators conducting ongoing and future clinical trials in patients with glioma should consider assessing MGMT promoter methylation status, and probably including this factor as a st ratification parameter.
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